Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 11/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 4/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253000 | 0.84 | HTR2A (0.39) | GRIN2BGRIN1KMOBRD4HTR2A | |
| SCHEMBL7256589 | 0.80 | GRIN2B (0.39) | GRIN2BGRIN1KMOBRD4HTR2A | |
| SCHEMBL7253398 | 0.79 | HTR1D (0.48) | KMOBRD4HTR2AHTR2CHTR2B | |
| SCHEMBL7256625 | 0.78 | MCHR1 (0.46) | GRIN2BKMOBRD4HTR2AHTR2C | |
| SCHEMBL7252961 | 0.74 | BRD4 (0.36) | KMOBRD4CHEK1HTR2AHTR2C | |
| SCHEMBL7252996 | 0.74 | HTR1D (0.52) | BRD4MET | |
| SCHEMBL7253683 | 0.74 | KMO (0.57) | KMOIRAK4HTR2AHTR2CHTR2B | |
| SCHEMBL7572923 | 0.74 | HTR2A (0.44) | KMOCHEK1HTR2AHTR2CHTR2B | |
| SCHEMBL7253556 | 0.73 | HTR1D (0.46) | KMOBRD4HTR2AHTR2CHTR2B | |
| SCHEMBL7256491 | 0.71 | HTR1D (0.47) | KMOBRD4HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | claimed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | claimed |
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | disclosed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | disclosed |
| US-6380242-B1 | FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS | NPS ALLELIX CORP. (CA) | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | CNR1, CNR2, KCNH1 | GRIN2B 316/4885GRIN1 303/4885KMO 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.